Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve

NCT07117682 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Diminished Ovarian Reserve (DOR)
Primary Ovarian Insufficiency (Poi)
Ovarian Failure, Premature

Interventions

DEVICE: Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection

Sponsor

Cytori Therapeutics

Collaborators

[object Object]